Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs - Takeaways - MDSpire
Commentary & Perspectives

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...

  • By

  • Lisa Astor

  • April 24, 2026

  • 9 min

Share

  • 1

    Inconsistent reporting of thrombotic events hinders patient care.

  • 2

    Thromboembolic events have critical implications for cancer treatment outcomes.

  • 3

    Rivaroxaban reduces the risk of venous thromboembolism by 60%.

  • 4

    Proper risk assessment and prophylaxis can improve management.

  • 5

    Accurate data reporting is essential in clinical trials.

  • 6

    Thromboembolism rates vary greatly by tumor location.

  • 7

    Call for mandatory reporting of all thrombotic events in trials.

Original Source(s)

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

  • by Lisa Astor

  • April 24, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 12, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...